NCT06630585
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
Recruiting · Phase 3 · University of Bern · registry updated 2026-01-26
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D. This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.
Inclusion
- Participants with diagnosed T1D for at least 12 months.
- Aged between 18 to 65 years old (inclusive).
- Currently on AID therapy for at least three months.
- HbA1C higher or equal to 6.5% and less or equal to 10%.
- BMI ≥23 kg/m2.
- Willing to use once-weekly tirzepatide for at least 16 weeks (including four weeks of up-titration and 12 weeks of treatment)
Exclusion
- History of diabetic ketoacidosis requiring hospitalization in the past six months.
- History of severe hypoglycemic event (Level 3, defined as seizure or loss of consciousness) in the past six months.
- Uncontrolled Diabetic retinopathy or maculopathy
- Severe gastroparesis.
- Less than 12 months of insulin treatment.
- Estimated glomerular filtration rate (eGFR) lab value below 30 mL/min/1.73 m2 by the CKD-EPI formula(99).